HomeCompareLBPH vs ARCC

LBPH vs ARCC: Dividend Comparison 2026

LBPH yields 3.33% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LBPH wins by $254.00 in total portfolio value· pulled ahead in Year 8
10 years
LBPH
LBPH
● Live price
3.33%
Share price
$59.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.8K
Annual income
$413.26
Full LBPH calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — LBPH vs ARCC

📍 LBPH pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLBPHARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LBPH + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LBPH pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LBPH
Annual income on $10K today (after 15% tax)
$283.43/yr
After 10yr DRIP, annual income (after tax)
$351.27/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, LBPH beats the other by $350.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LBPH + ARCC for your $10,000?

LBPH: 50%ARCC: 50%
100% ARCC50/50100% LBPH
Portfolio after 10yr
$24.7K
Annual income
$207.21/yr
Blended yield
0.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

LBPH
Analyst Ratings
5
Buy
4
Hold
Consensus: Buy
Price Target
$61.00
+1.7% upside vs current
Range: $16.00 — $90.00
Altman Z
63.6
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LBPH buys
0
ARCC buys
0
No recent congressional trades found for LBPH or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLBPHARCC
Forward yield3.33%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$24.8K$24.5K
Annual income after 10y$413.26$1.16
Total dividends collected$3.8K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$61.00$21.88

Year-by-year: LBPH vs ARCC ($10,000, DRIP)

YearLBPH PortfolioLBPH Income/yrARCC PortfolioARCC Income/yrGap
1$11,033$333.44$11,381$541.15$348.00ARCC
2$12,150$343.84$12,621$284.08$471.00ARCC
3$13,354$353.85$13,827$145.31$473.00ARCC
4$14,652$363.48$15,062$73.43$410.00ARCC
5$16,051$372.73$16,364$36.89$313.00ARCC
6$17,556$381.59$17,757$18.49$201.00ARCC
7$19,175$390.07$19,258$9.25$83.00ARCC
8← crossover$20,915$398.17$20,880$4.63+$35.00LBPH
9$22,785$405.89$22,636$2.32+$149.00LBPH
10$24,793$413.26$24,539$1.16+$254.00LBPH

LBPH vs ARCC: Complete Analysis 2026

LBPHStock

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Full LBPH Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this LBPH vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LBPH vs SCHDLBPH vs JEPILBPH vs OLBPH vs KOLBPH vs MAINLBPH vs HTGCLBPH vs GBDCLBPH vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.